Biogen (HAM:IDP) Other Current Liabilities: €167 Mil (As of Mar. 2026)


HAM:IDP Biogen Inc HAM:IDP
74 GF Score
Price €173.82
GF Value €167.59
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Biogen Other Current Liabilities?

Biogen HAM:IDP -0.84% 74 Other Current Liabilities is €167 Mil as of Mar. 2026. GuruFocus rates HAM:IDP with a GF Score™ of 74/100 and a GF Value™ of €167.59 (Fairly Valued). The stock has 7 warning signs investors should review.

Biogen's other current liabilities for the quarter that ended in Mar. 2026 was €167 Mil.

Biogen's quarterly other current liabilities declined from Sep. 2025 (€341 Mil) to Dec. 2025 (€321 Mil) and declined from Dec. 2025 (€321 Mil) to Mar. 2026 (€167 Mil).

Biogen's annual other current liabilities increased from Dec. 2023 (€307 Mil) to Dec. 2024 (€359 Mil) but then declined from Dec. 2024 (€359 Mil) to Dec. 2025 (€321 Mil).

Biogen Other Current Liabilities Related Terms

Biogen Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Biogen's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Other Current Liabilities Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 305.41 1,078.52 307.29 358.89 320.93

Biogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 177.88 333.45 340.63 320.93 166.51
HAM:IDP
74GF Score
Biogen Inc HAM:IDP
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €167 Mil mean?
Biogen (HAM:IDP) has a Other Current Liabilities of €167 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Biogen.
Is Biogen's Other Current Liabilities too high?
Biogen's current Other Current Liabilities is €167 Mil. Overall, Biogen has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Other Current Liabilities compare to OGN and AMRN?
Biogen's Other Current Liabilities of €167 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Biogen. Biogen's current Other Current Liabilities is €167 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (HAM:IDP) is currently considered Fairly Valued. The stock's GF Value™ is €167.59, compared to a current price of €173.82 — trading 3.7% above its estimated fair value. The current Other Current Liabilities is €167 Mil. Biogen's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Biogen (HAM:IDP), the current Other Current Liabilities is €167 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (HAM:IDP) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of €173.82 is trading 3.7% above its estimated GF Value™ of €167.59. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for HAM:IDP:

  • Other Current Liabilities: €167 Mil
  • GF Value™: €167.59 vs. price of €173.82 (3.7% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the HAM:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
74GF Score

Get the complete analysis for HAM:IDP

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€173.82
Price
€167.59
GF Value